Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 93, Issue 5, Pages 704-715
Publisher
Wiley
Online
2018-04-10
DOI
10.1002/ajh.25071
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
- (2018) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
- (2018) Joseph M. Connors et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
- (2017) Marc P.E. André et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group
- (2017) Dennis A Eichenauer et al. LANCET ONCOLOGY
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
- (2016) Peter Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Craig H Moskowitz et al. LANCET
- Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma
- (2015) John Radford et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis
- (2013) Nicole Skoetz et al. LANCET ONCOLOGY
- Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
- (2013) Anas Younes et al. LANCET ONCOLOGY
- Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
- (2012) A. Younes et al. BLOOD
- Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma
- (2012) Y. L. Kasamon et al. BLOOD
- Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial
- (2012) Bastian von Tresckow et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)
- (2012) Leo I. Gordon et al. JOURNAL OF CLINICAL ONCOLOGY
- Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
- (2012) Andreas Engert et al. LANCET
- PI3K inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma
- (2011) S. A. Meadows et al. BLOOD
- Long-Term Follow-Up Analysis of HD9601 Trial Comparing ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study From the Intergruppo Italiano Linfomi
- (2011) Teodoro Chisesi et al. JOURNAL OF CLINICAL ONCOLOGY
- Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
- (2011) Anas Younes et al. LANCET ONCOLOGY
- ABVD versus BEACOPP for Hodgkin's Lymphoma
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Hodgkin's Lymphoma — The Great Teacher
- (2011) Joseph M. Connors NEW ENGLAND JOURNAL OF MEDICINE
- ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned
- (2011) Simonetta Viviani et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma
- (2011) Ralph M. Meyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma
- (2010) Sally F. Barrington et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial
- (2010) Hans Theodor Eich et al. JOURNAL OF CLINICAL ONCOLOGY
- Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
- (2010) Andreas Engert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study
- (2009) Andreas Engert et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244
- (2009) Peter J. Hoskin et al. JOURNAL OF CLINICAL ONCOLOGY
- ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
- (2009) Massimo Federico et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery ofN-(2-Aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an Orally Active Histone Deacetylase Inhibitor
- (2008) Nancy Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
- (2008) M. Fournel et al. MOLECULAR CANCER THERAPEUTICS
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now